Audit: QRS - Cryotherapy for Health & Longevity

Audit conducted on 29/08/2026 07:09 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol cells, time-to-effect cells, all four benefit tiers, all four risk tiers, the 12 contraindications, the 10 interactions, the 10 biomarkers and the 6 qualitative items each trace to a specific ER passage.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	ER’s “an extrapolation from acclimation studies, not a tested prescription” is carried as “extrapolated, not a tested prescription” in action_3_sub; ER’s “not brief extreme cold” is carried as “Requires sustained exposure, not brief sessions” in time_3_sub.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy, alcohol/sedatives and long-QT remain in the Contraindications gate at ER strength; no ER caution is downgraded to a note or upgraded to a directive.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications and Key Interactions both come from Key Interactions & Contraindications; benefits from Expected Benefits; risks from Potential Risks & Side Effects. No Benefit- or Risk-Modifying Factor is surfaced anywhere.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS contains no PMIDs, citations, author names, NCT identifiers or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The ER’s balanced-but-sceptical register (narrow solid results set against a well-replicated adaptation cost) is reproduced in At-A-Glance and across the benefit/risk tiers.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	At-A-Glance leads with what is best supported before naming the costs; monitoring targets and protocol cells give the reader concrete, actionable anchors.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated descriptively (“Practitioners use…”, “A widely used target is…” condensed into noun-phrase cells) with no imperatives.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Monitoring targets and cadence are presented as reference ranges and schedules, not as instructions to the reader.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should” or “must” anywhere in the sheet.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	Verified: no second-person pronoun (“you”, “your”, “yours”) occurs in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained are only those load-bearing for the decision gates and monitoring table and are used verbatim from the ER; At-A-Glance is fully plain-language.
2.8	Information is presented in a concise and very compact manner	🟢	Every gate item, benefit tier and risk tier is a stripped noun phrase; no sentence-length elaborations.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-file second-person scan; no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	The sheet assumes a reader who will screen cardiovascular status, track ten biomarkers and time cold around training blocks.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Six-to-ten chamber sessions over 2–3 weeks and a weekly cold budget are presented without hedging about burden or cost.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No general-population framing, no “ask your doctor first” softening beyond the fixed footer disclaimer.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The hypertrophy cost is placed at the top of the High risk tier — the signal that matters specifically to a training, optimisation-oriented reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the speculative benefit is framed as “Slowed biological aging” and the title uses “Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal register throughout (“myocardial infarction”, “corrected QT interval”, “adverse events”, “cold urticaria”); no consumer-grade substitutions.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fifteen fixed strings match the template byte-for-byte (lines 440, 477, 519, 539, 558, 580, 599, 603–605, 729, and the four tier labels in each of the Benefits and Risks cards).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Set comparison of all data-qrs-var names against the template (with marker_#/qualitative_item_# normalised) is identical — no span added, renamed or dropped.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A structural diff against the template with span contents masked shows only the expected repetition of the monitoring <tr> and qualitative <li> blocks; every other line, comment, style rule and non-data-qrs-var span (website="evidence_review", website="audit", website="full_review") is unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty; every benefit tier, risk tier, gate list, protocol and monitoring source is populated.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1_label “Standard chamber protocol”, action_2_label “Standard immersion protocol” and action_3_label “Weekly dose framing” are the ER’s bold Therapeutic Protocol labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No protocol label is shortened or reworded; monitoring row labels match the ER biomarker table’s first column exactly.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Full-file scan finds no 🟩, 🟥, 🟨 or ⚠️; tiering is carried by the <strong> labels plus the .benefits/.risks CSS palettes.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every ER section is condensed to the template’s fixed slot count (3 protocol cells, 3 time cells, 4 benefit tiers, 4 risk tiers, two gate lists, one 10-row table, 6 qualitative items); no slot or block was duplicated to gain space.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14: the comment opens on line 2 immediately after <!doctype html> on line 1 and closes on line 14, before the template’s own comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3 and closing --- at line 13, preceded only by the permitted “QRS — Metadata …” text on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	The block sits entirely inside an HTML comment and none of its values are repeated in <head> or <body> other than where a checklist item requires it (topic, date, model).
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, and it must be because the value contains a colon; all other values are bare and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: cryotherapy_2026-0829-0448_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0829-0614, correct YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: cryotherapy_2026-0829-0448_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including git_user: evipedia-4 and git_issue: 5590; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Cryotherapy for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Cryotherapy for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/29/2026, the correct MM/DD/YYYY rendering of 2026-0829-0614.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header block (lines 415–428) contains only the title and the template’s fixed subline; the ER’s “Also known as” list and creator attribution are not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Line 433 compresses the Conclusion’s four load-bearing moves: what cryotherapy is, the best-supported outcomes, the replicated costs, and the animal-only basis of the aging claim.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words (60 whitespace tokens, one of which is a standalone em-dash).
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct Conclusion sentence: chamber/water definition, rheumatic pain, depression scores, soreness, hypertrophy cost, blood pressure, skin burns, animal-only aging evidence.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “inflammatory joint disease” rather than “rheumatoid arthritis/ankylosing spondylitis”, “muscle growth” rather than “hypertrophy”, “cold water” rather than “cold-water immersion”; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No author names, years, sample sizes or p-values appear.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No standardised mean differences, Hedges’ g, incidence rate ratios or confidence intervals appear.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All twelve stop_items come from that ER section — eleven from the “Populations who should avoid Cryotherapy” list and one from the alcohol/sedatives bullet marked “absolute contraindication before immersion”.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete one-to-one coverage of the ER’s eleven avoid-list bullets plus the alcohol/sedative absolute contraindication; nothing added, nothing omitted.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 542–553: twelve well-formed <li>…</li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Explanatory glosses are stripped (“cold-triggered destruction of red blood cells”, “including advanced diabetic neuropathy”, “Mitigation: no cold exposure while intoxicated or sedated”); no dash-introduced trailing clause survives.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	”(<90 days)”, “(≥180/110 mmHg)”, “(>480 ms)”, “New York Heart Association Class III–IV” and “(diphenhydramine)” are all carried through; none of the ER’s thresholds, windows or staging is dropped.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses; the only > is the numeric threshold “corrected QT >480 ms”, which is a comparison operator, not severity ordering.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, which is correct: the ER explicitly names eleven populations that should avoid cryotherapy plus one absolute pre-immersion contraindication.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty, so no absence-basis comment is required.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten caution_items map to the ER’s bulleted interaction entries in that section.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The ER lists eleven interaction bullets; the alcohol/sedating-agents bullet is correctly routed to the Contraindications gate and excluded here, leaving exactly ten.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 561–570: ten well-formed <li>…</li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER “— caution/monitor/interaction:” clause and every “Mitigation:” sentence is stripped; each item reduces to the agent or exposure class alone.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drugs are carried for every bullet that has them: “(metoprolol, atenolol, propranolol)”, “(sumatriptan, ergotamine, pseudoephedrine)”, “(amphetamines, methylphenidate, high-dose caffeine)”, “(warfarin, apixaban, aspirin)”, “(ibuprofen, naproxen)”, “(vitamin C 1000 mg, vitamin E 400 IU)”, “(citrulline, beetroot nitrate)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets contain no ranking notation inside parentheses; all parentheses hold plain comma-separated drug lists.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, which is correct: the ER documents ten distinct interactions and additive effects.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty, so no absence-basis comment is required.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER’s Therapeutic Protocol bullets (standard chamber protocol, standard immersion protocol, weekly dose framing).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The two delivery modalities that carry all the trial evidence plus the widely used weekly-dose target are the three actionable aspects; the remaining ER bullets are modifiers (timing, genotype, sex, age) rather than implementation aspects.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies at least three distinct actionable aspects, so all three sets are used and none needed hiding.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine cells populated: “2–3 min at −110 °C to −140 °C” / “6–10 sessions over 2–3 weeks, dry clothing, extremities covered”; “10–15 °C for 5–15 min” / “To the neck or waist, daily or several times weekly”; “~11 min of cold per week” / “Across two to four sessions; extrapolated, not a tested prescription” — each matching the ER verbatim in substance.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s Practical Considerations “Time to effect” bullet names exactly three horizons — immediate analgesia/mood, 3–6 sessions for rheumatic symptom change, ~10 days for metabolic acclimation — and all three are carried.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order is rheumatic symptom change (the ER’s first High-tier benefit), then pain relief and mood lift (also High tier), then metabolic acclimation (Medium tier) — non-increasing by benefit magnitude.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells populated: “3–6 sessions” / “Pain and measured disease activity”; “Immediate” / “Last hours”; “~10 days” / “Requires sustained exposure, not brief sessions”.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eleven benefit entries correspond one-to-one to the ER’s Expected Benefits sub-headings across the four tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 521–532.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the ER sub-heading reduced to a bare outcome phrase; the “Magnitude:” paragraphs, mechanism sentences and evidence descriptions are all dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four benefit spans; the ER’s “(early memory and thinking decline that falls short of dementia)” gloss and all effect sizes are stripped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All twelve risk entries correspond one-to-one to the ER’s Potential Risks & Side Effects sub-headings across the four tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at lines 582–593.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is a bare risk phrase; “Magnitude:” figures such as the −0.60 pooled SMD, the 27.6% rash rate and the 438→457 ms QT change are all excluded.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four risk spans; the ER’s glosses for “afterdrop”, “anaphylaxis” and “paraesthesia” are stripped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table and cadence both derive from the ER’s Monitoring Protocol & Defining Success section.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten rows of the ER biomarker table are present in the same order with matching targets: hs-CRP <1.0 mg/L; blood pressure <120/80 mmHg; corrected QT <450/<460 ms; rMSSD stable or rising vs own 7-day baseline; fasting insulin 2–5 µIU/mL; HbA1c 4.8–5.4%; triglycerides <80 mg/dL; total testosterone 600–900 ng/dL; creatine kinase <200 U/L at rest; TSH 0.5–2.0 mIU/L.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 723 carries the ER’s cadence in full: baseline before first exposure, reassessment at 4 and 12 weeks then 6-monthly, with weekly blood pressure and skin checks through the first month.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the ER’s qualitative-marker bullet list at the end of Monitoring Protocol & Defining Success.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER bullets are carried in order: morning mood and drive; joint stiffness and pain on a 0–10 scale weekly; sleep latency and night awakenings; cold tolerance/time to shivering; training quality; skin condition after each session.

Issues 29/08/2026 07:09

Pass rate 100.00%. No issues found.

Issues 29/08/2026 07:03

1. 2.15 — Truncated clinical terms in gate: Two contraindication items shorten clinical terminology below formal usage — line 542 reads “infarction” where the ER says “myocardial infarction” (ER line 358), and line 547 reads “Raynaud” where the ER says “Raynaud phenomenon” (ER line 363).

Fixes 29/08/2026 07:03

1. 2.15 — Truncated clinical terms in gate: Restored formal terminology in two contraindication items — “infarction” to “myocardial infarction” and “Raynaud” to “Raynaud phenomenon”, matching the ER wording.

Issues 29/08/2026 06:55

1. 4.5 — One-page budget exceeded: At 9.5pt in a half-width gate column the 12 contraindication items (lines 542–553) plus 10 key-interaction items (lines 561–570), stacked with a 10-row monitoring table, 6 qualitative items and four-item tier lines such as risks_medium (line 586), overrun the single A4 page the sheet is designed for.

Fixes 29/08/2026 06:55

1. 4.5 — Contraindication items condensed: Shortened seven of the twelve stop_items so each fits a single line in the half-width gate column, keeping every condition and every threshold (e.g. “Symptomatic arrhythmia, long QT (corrected QT >480 ms), implanted defibrillator” → “Symptomatic arrhythmia, long QT (>480 ms), defibrillator”; “Untreated seizure disorder, or any cause of loss of consciousness in water” → “Untreated seizure disorder; unconsciousness risk in water”).
2. 4.5 — Key interaction items condensed: Trimmed six caution_items to class plus example drug list with no example dropped (e.g. “High-dose antioxidant supplements (vitamin C 1000 mg, vitamin E 400 IU)” → “High-dose antioxidants (vitamin C 1000 mg, vitamin E 400 IU)”; “Resistance training and blood-flow restriction training” → “Resistance and blood-flow restriction training”).
3. 4.5 — Long tier lines shortened: Cut the four-item risks_medium line from 185 to 156 characters (“hypothermia and afterdrop in prolonged immersion” → “hypothermia and afterdrop”; “after extended cold-water swimming” → “after long cold-water swims”) and trimmed “after hard exercise” to “after exercise” in benefits_high.

Issues 29/08/2026 06:47

1. 12.3 — Mechanism retained in speculative benefit: [benefits_speculative] at line 531 reads “suppression of tumour growth via brown fat activation”; the trailing mechanistic clause “via brown fat activation” is an explanation that section 12.3 requires to be stripped down to the key fact.

Fixes 29/08/2026 06:47

1. 12.3 — Mechanism stripped from speculative benefit: Changed [benefits_speculative] from “suppression of tumour growth via brown fat activation” to “suppressed tumour growth”, removing the mechanistic clause.

Issues 29/08/2026 06:40

1. 2.7 — Unnecessary medical jargon in label: [time_2_label] reads “Analgesia and mood lift” (QRS line 494); “analgesia” is specialist vocabulary carried over without the plain-language gloss the ER supplies at first use.

Fixes 29/08/2026 06:40

1. 2.7 — Jargon replaced in time label: Changed [time_2_label] from “Analgesia and mood lift” to “Pain relief and mood lift”, using the plain-language term the ER itself supplies as the gloss for “analgesia”.

Issues 29/08/2026 06:34

1. 2.5 — Imperative verb in cadence: [monitoring_cadence] at line 723 reads “reassess at 4 and 12 weeks”, an instruction to the reader, where the ER uses the nominal form “reassessment at 4 weeks, at 12 weeks” (ER line 479).

Fixes 29/08/2026 06:34

1. 2.5 — Imperative verb in cadence: Changed [monitoring_cadence] from “reassess at 4 and 12 weeks” to “reassessment at 4 and 12 weeks”, restoring the ER’s nominal form so the sheet presents information rather than instructing the reader.

Issues 29/08/2026 06:26

1. 1.3 — Soreness benefit modality dropped: The At-A-Glance (QRS line 433) presents “less muscle soreness after hard exercise” as a best-supported effect of cryotherapy generally, while the ER Conclusion (line 525) restricts it to cold water and calls the chamber trials “too small and too flawed to settle”.

Fixes 29/08/2026 06:26

1. 1.3 — Soreness benefit modality restored: In [at_a_glance], changed “less muscle soreness after hard exercise” to “less muscle soreness after hard exercise with cold water”, matching the ER Conclusion’s restriction of that finding to cold-water immersion.

Issues 29/08/2026 06:20

1. 4.5 — Sheet overflows one A4 page: The populated QRS renders to roughly 1.8 A4 pages; the 12-item contraindication gate (lines 542–553), the 10-row monitoring table (lines 609–718) and the benefits/risks cards were transferred at full ER length rather than condensed to a per-section budget.
2. 2.8 — ER prose copied, not condensed: [monitoring_cadence] (line 723), [qualitative_item_5] (line 744), [marker_8_why] (line 694) and [action_3_sub] (line 472) reproduce full ER sentences with subordinate clauses instead of compact statements.

Fixes 29/08/2026 06:20

1. 4.5 / 2.8 — Contraindication gate condensed: All twelve contraindication items were shortened to reduce the tallest block on the sheet, keeping every threshold and qualifier (e.g. “Uncontrolled hypertension (resting blood pressure ≥180/110 mmHg)” to “Uncontrolled hypertension (≥180/110 mmHg)”; the duplicated “alcohol” in the sedating-agents item was removed).
2. 4.5 — Benefits and risks tiers trimmed: Redundant wording was cut from all seven tier lines (e.g. “reduced muscle soreness and faster perceived recovery after hard exercise” to “reduced muscle soreness after hard exercise”; “cold-induced airway narrowing in people with asthma” to “airway narrowing in asthma”).
3. 4.5 / 2.8 — Monitoring “Why” column shortened: Nine of the ten marker rationales were reduced to a single clause (e.g. marker_8_why from “Cold blunts the post-exercise anabolic response; a falling trend suggests excessive load” to “A falling trend suggests excessive load”).
4. 2.8 — Monitoring cadence compacted: [monitoring_cadence] was cut from 163 to 132 characters, from the ER’s full sentence to “Baseline before first exposure; reassess at 4 and 12 weeks, then 6-monthly; blood pressure and skin checks weekly for the first month”.
5. 2.8 — Qualitative items shortened: Items 4, 5 and 6 were compacted (e.g. item 5 from “Training quality: session readiness, perceived exertion at fixed loads, and whether strength is still progressing” to “Training quality: readiness, perceived exertion at fixed loads, strength progression”).
6. 2.8 — Protocol sub-lines trimmed: All three [action_#_sub] lines were shortened, notably action_3_sub from “Divided across two to four sessions; an extrapolation from acclimation studies, not a tested prescription” to “Across two to four sessions; extrapolated, not a tested prescription”.